Effectiveness of oral antibiotics for definitive therapy of non-Staphylococcal Gram-positive bacterial bloodstream infections
| Autor: | Jamielynn C Sebaaly, Nicholas J Quinn, Danya Roshdy, David A Weinrib, William E. Anderson, Bianka A Patel |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.drug_class business.industry Definitive Therapy 030106 microbiology Antibiotics oral antibiotics Infectious and parasitic diseases RC109-216 medicine.disease 03 medical and health sciences Gram-positive 0302 clinical medicine Infectious Diseases Internal medicine Bacteremia medicine Pharmacology (medical) 030212 general & internal medicine bacteremia business bioavailability Original Research |
| Zdroj: | Therapeutic Advances in Infectious Disease Therapeutic Advances in Infectious Disease, Vol 6 (2019) |
| ISSN: | 2049-9361 |
| Popis: | Background:Data on the effectiveness of definitive oral (PO) antibiotics for BSIs in preparation for discharge from hospital are lacking, particularly for Gram-positive bacterial BSIs (GP-BSI). The objective of this study was to determine rates of treatment failure based on bioavailability of PO antimicrobial agents used for GP-BSI.Methods:This was a single-center, retrospective cohort study of adult inpatients admitted to an academic medical center over a three-year period. Patients with a non-staphylococcal GP-BSI who received intravenous antibiotics and were then switched to PO antibiotics for at least a third of their treatment course were included. The cohort was stratified into high (⩾90%) and low (Results:A total of 103 patients met criteria for inclusion, which failed to reach the a priori power calculation. Of the patients included, 26 received high bioavailability agents and 77 received low bioavailability agents. Infections originated largely from a pulmonary source (30%) and were caused primarily by streptococcal species (75%). Treatment failure rates were 19.2% in the high bioavailability group and 23.4% in the low bioavailability group ( p = 0.66). Clinical failure stratified by subgroups also did not yield statistically significant differences.Conclusions:Clinical failure rates were similar among patients definitively treated with high or low bioavailability agents for GP-BSI, though the study was underpowered to detect such a difference. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|